SonoMind

Sonomind is a medical device company specializing in non-invasive brain stimulation utilizing low-intensity focused ultrasound to treat drug-resistant depression and other neurological and psychiatric conditions. This portable device is the first to deliver precision transcranial ultrasound stimulation that is able to penetrate deep brain structures in an accurate, targeted and non-invasive manner. A custom-designed acoustic lens for each patient delivers low-intensity focused ultrasound, enabling ultrasound waves to pass through the skull and compensate for any distortion upon entering the brain. Located in Paris, France, Sonomind has a staff of ten, headed by CEO Jeremy Bercoff. The company leverages 25 years of research undertaken by Profs. Mickael Tanter and Jean-François Aubry at the Institut Physique pour la Médecine (Inserm, ESPCI Paris - PSL, CNRS). Sonomind has raised €2 million since inception